In response to the NDMA findings, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have taken decisive actions. The FDA requested the removal of all ranitidine products from the market in April 2020. Similarly, the EMA suspended ranitidine products from the European market. These actions were taken to protect public health and limit exposure to potentially harmful levels of NDMA.
